Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Dana-Farber Cancer Institute · Massachusetts General Hospital · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
657
total citations
- FWCI
- 68.01
- Percentile
- 100%
- References
- 35
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Selumetinib
- Docetaxel
- Medicine
- KRAS
- Placebo
- Lung cancer
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.